InsiderTrades.com logo
Better than Bitcoin? The Biotech Stock with 46,751% Potential
From Behind the Markets   |   Ad
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Get the name of the stock here >>>

BNO Insider Trading

Insider Ownership Percentage: 7.19%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Bionomics Insider Trading History Chart

This chart shows the insider buying and selling history at Bionomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bionomics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for BNO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Better than Bitcoin? The Biotech Stock with 46,751% Potential
From Behind the Markets   |   Ad
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Get the name of the stock here >>>

Bionomics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2023Errol De SouzaInsiderIssued10,000,000A$0.03A$290,000.00
11/28/2022Alan FisherInsiderExpiry100,000A$0.07A$6,600.00
12/22/2021Errol De SouzaInsiderIssued61,216,767A$0.12A$7,039,928.21
See Full Table
Better than Bitcoin? The Biotech Stock with 46,751% Potential
From Behind the Markets   |   Ad
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Get the name of the stock here >>>

SEC Filings (Institutional Ownership Changes) for Bionomics (ASX:BNO)

29.33% of Bionomics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Read More on Bionomics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

386,458 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13

Who are the company insiders with the largest holdings of Bionomics?

Bionomics' top insider shareholders include:
  1. Alan Fisher (Insider)
  2. Errol De Souza (Insider)
Learn More about top insider investors at Bionomics.
Better than Bitcoin? The Biotech Stock with 46,751% Potential
From Behind the Markets   |   Ad
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Get the name of the stock here >>>